BUY Aurobindo Pharma — Kavita Jain, 08 Sept 2026

byKavita Jain, Arihant Capital MarketsHorizon: NA (inferred Swing (≤2wk))8 Sept 2026via CNBC Awaaz.

Entry₹1,685Inferred

Target₹1,715

Stop loss₹1,671-0.83% risk

CMP₹1,698.915h ago

Active+0.82%+0.95%upside left 13d left

Follow Kavita Jain for new calls(48% target hit, 54 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 3 other Swing calls on AUROPHARMA See 264 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 10 Sept, 7:25 am IST

6 supporting5 neutral2 opposing

Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·10 Sept · today

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·8 Sept · yesterday

Aurobindo stock gains on generic Advair launch

NewsGoogle News·1 Sept · 1w ago

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

NewsEt-Markets·31 Aug · 1w ago

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.

NSE · Press Release·31 Aug · 1w ago

Neutral / worth noting (5)

Upcoming Stock Split, Dividend, Bonus Issue THIS Week: Aurobindo Pharma, Muthoot Finance, More | Full List

NewsGoogle News·5 Sept · 4d ago

Aurobindo Pharma moves up as its arm incorporates wholly owned subsidiary

NewsGoogle News·2 Sept · 1w ago

Aurobindo Pharma arm Apitoria incorporates Avogent Lifesciences as subsidiary

NewsGoogle News·1 Sept · 1w ago

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · 1w ago

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 2w ago

Weighs against the BUY call (2)

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 2w ago

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Aurobindo Pharma — Kavita Jain, Arihant Capital Markets

AI Assessment